Targeted therapy doubles progression-free survival in rare bile duct cancer
A phase 2 clinical trial for the drug zenocutuzumab has shown promising results in treating rare bile duct cancers with NRG1 gene fusions. The therapy successfully doubled progression-free survival rates in patients with manageable side effects.
Why it matters
This represents a significant advancement in targeted cancer therapy, offering new hope for patients with specific genetic mutations in hard-to-treat solid tumors.
Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member Targeted therapy doubles progression-free survival in rare bile duct cancer Download PDF Copy Add News Medical on Google as a preferred source Dana-Farber Cancer Institute Jul 2 2026 Reviewed Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 ( NRG1 ) gene fusions, reported manageable side effects and clinically meaningful efficacy - including a near doubling of progression-free survival compared to expectations with standard of care - in previously treated patients with advanced NRG1 -positive cholangiocarcinoma. Based on these results, the U.S. Food and Drug Administration approved zenocutuzumab as second-line therapy for NRG1 -positive cholangiocarcinoma on May 8.
The article provides a straightforward summary of medical trial results.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in